bps804
mAbexperimental
Clinical trial activity
10 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
9
Phase 3
3
Phase 4
0
Earliest trial started Jun 1, 2011 (NCT01417091)
Timeline
Indications
Mechanism of action
- SclerostinINHIBITOR
Sclerostin inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297918 ↗
Also known as
- bps804
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06636071 | Phase 3 | Oct 31, 2024 | Ultragenyx Inc. |
| NCT05768854 | Phase 3 | Jun 14, 2023 | Ultragenyx Inc. |
| NCT05312697 | Phase 2 | Apr 28, 2022 | Mereo BioPharma, Ultragenyx Inc. |
| NCT05125809 | Phase 2/Phase 3 (Phase 3) | Dec 31, 2021 | Mereo BioPharma, Ultragenyx Inc. |
| NCT03216486 | Phase 2 | Oct 31, 2017 | Baylor University, ICON, Mereo BioPharma |
| NCT03118570 | Phase 2 | Sep 11, 2017 | Mereo BioPharma, Ultragenyx Inc. |
| NCT01806610 | Phase 2 | Aug 1, 2013 | Novartis |
| NCT01406548 | Phase 2 | Jul 1, 2011 | Novartis |
| NCT01406977 | Phase 2 | Jul 1, 2011 | Novartis |
| NCT01417091 | Phase 2 | Jun 1, 2011 | Novartis |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ultragenyx Inc. | For profit | 5 | 5 | 2 | 2017 |
| Mereo BioPharma | For profit | 4 | 1 | 2 | 2017 |
| Novartis | For profit | 4 | 4 | 1 | 2011 |
| Baylor University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| ICON | For profit | 1 | 0 | 1 | 2017 |
5 organizations
Page 1 / 1